Journal
CANCER CELL
Volume 32, Issue 5, Pages 608-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2017.10.004
Keywords
-
Categories
Funding
- Castilla-Leon Government [BIO/SA01/15, CSI049U16]
- Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2015-64556-R, RD12/0036/0002]
- Worldwide Cancer Research [141248]
- Ramon Areces Foundation
- Spanish Society Against Cancer
- MINECO [PI13/00448, SAF2013-40922-R, RD12/0036/0054, SAF2013-44857-R, RD12/0036/0075]
- European Regional Development Fund
Ask authors/readers for more resources
Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are deemed as potential therapeutic targets owing to their protumorigenic functions. However, the understanding of the spectrum of their pathobiological roles in tumors is still very limited. We report here that the GEF Vav1 unexpectedly possesses tumor-suppressor functions in immature T cells. This function entails the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is essential for the pathogenesis of human T-ALL of the TLX+ clinical subtype, further underscoring the suppressor role of this pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available